| 马成虎,马 尚,傅思武,等.乳腺癌抗体药物偶联物耐药机制的研究进展[J].肿瘤学杂志,2025,31(7):586-591. |
| 乳腺癌抗体药物偶联物耐药机制的研究进展 |
| Progress on Resistance Mechanisms of Antibody-Drug Conjugate in Breast Cancer |
| 投稿时间：2024-12-19 |
| DOI：10.11735/j.issn.1671-170X.2025.07.B004 |
|
 |
| 中文关键词: 乳腺肿瘤 抗体药物偶联物 耐药 治疗 |
| 英文关键词:breast neoplasms antibody-drug conjugate resistance treatment |
| 基金项目:兰州市科技计划项目（2024-4-47） |
|
| 摘要点击次数: 202 |
| 全文下载次数: 122 |
| 中文摘要: |
| 摘 要： 抗体药物偶联物（antibody-drug conjugate，ADC）有效地改善了乳腺癌患者的临床结局，但随着应用越来越广泛，其耐药性问题常导致治疗失败。ADC耐药的机制归纳为抗原相关耐药、ADC内化和循环失调、有效载荷耐药、有效载荷靶标的改变以及信号通路改变的耐药。全文通过深入解析ADC耐药机制，提出多维度策略以突破ADC耐药瓶颈，实现精准耐药干预，以期进一步提高ADC在乳腺癌中的疗效，增加患者获益。 |
| 英文摘要: |
| Abstract： Antibody-drug conjugate (ADC) have emerged as a transformative approach to improving clinical outcomes for breast cancer patients. However， the increasing clinical application of ADC has revealed drug resistance as a critical challenge frequently leading to treatment failure. Mechanisms of ADC resistance can be categorized into antigen-related resistance， impaired ADC internalization and trafficking， payload resistance， alterations in payload targets， and resistance due to altered signaling pathways. Through comprehensive analysis of these resistance mechanisms， multi-dimensional strategies are proposed to overcome ADC resistance barriers， which would enable precise resistance interventions， ultimately enhancing therapeutic efficacy and maximizing clinical benefits for breast cancer patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |